The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Myfenax mycophenolate mofetil Generic | Teva B.V. | Graft Rejection | 🇪🇺 EU 2008-02-21 | Order → |
| Abraxane paclitaxel | Bristol-Myers Squibb Pharma EEIG | Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2008-01-11 | Order → |
| Avamys fluticasone furoate | GlaxoSmithKline Trading Services Limited | Rhinitis, Allergic, Seasonal; Rhinitis, Allergic, Perennial | 🇪🇺 EU 2008-01-11 | Order → |
| Ivemend fosaprepitant | Merck Sharp & Dohme B.V. | Vomiting; Cancer | 🇪🇺 EU 2008-01-11 | Order → |
| Tesavel sitagliptin | Merck Sharp & Dohme B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2008-01-10 | Order → |
| Isentress raltegravir Accelerated assessment | Merck Sharp & Dohme B.V. | HIV Infections | 🇪🇺 EU 2007-12-19 | Order → |
| Retacrit epoetin zeta Biosimilar | Pfizer Europe MA EEIG | Anemia; Blood Transfusion, Autologous; Kidney Failure, Chronic; Cancer | 🇪🇺 EU 2007-12-18 | Order → |
| Silapo epoetin zeta Biosimilar | Stada Arzneimittel AG | Anemia; Blood Transfusion, Autologous; Cancer; Kidney Failure, Chronic | 🇪🇺 EU 2007-12-18 | Order → |
| Atripla efavirenz;emtricitabine;tenofovir disoproxil | Gilead Sciences Ireland UC | HIV Infections | 🇪🇺 EU 2007-12-13 | Order → |
| Olanzapine Teva olanzapine Generic | Teva B.V. | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2007-12-12 | Order → |
| Glubrava pioglitazone;metformin | Takeda Pharma A/S | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2007-12-11 | Order → |
| Nevanac nepafenac | Novartis Europharm Limited | Pain, Postoperative; Ophthalmologic Surgical Procedures | 🇪🇺 EU 2007-12-11 | Order → |
| Vectibix panitumumab | Amgen Europe B.V. | Colorectal Neoplasms | 🇪🇺 EU 2007-12-03 | Order → |
| Cyanokit hydroxocobalamin | SERB SA | Poisoning | 🇪🇺 EU 2007-11-23 | Order → |
| Tasigna nilotinib | Novartis Europharm Limited | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 🇪🇺 EU 2007-11-19 | Order → |
| Torisel temsirolimus | Pfizer Europe MA EEIG | Carcinoma, Renal Cell; Lymphoma, Mantle-Cell | 🇪🇺 EU 2007-11-19 | Order → |
| Eucreas vildagliptin;metformin | Novartis Europharm Limited | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2007-11-14 | Order → |
| Olanzapine Cipla (previously Olanzapine Neopharma) olanzapine Generic | Cipla (EU) Limited | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2007-11-14 | Order → |
| Zalasta olanzapine Generic | KRKA tovarna zdravil d.d. Novo mesto | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2007-09-27 | Order → |
| Galvus vildagliptin | Novartis Europharm Limited | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2007-09-25 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.